Men with both high risk and intermediate risk prostate cancer will receive primary treatment and many also receive a second line of treatment. In a study that was designed to assess the impact of receiving both first and second line treatment on a man’s Health Related Quality of Life (HRQoL), researchers determined that men who received first line therapy suffered a decline in their HRQoL and those who also received a second line of therapy suffered an even greater decline.
The study was a prospective cohort study, which was begun in 2007. The researchers evaluated the longitudinal patterns in HRQoL in men treated by: surgery only, EBRT radiation only, EBRT + hormone therapy (ADT), or surgery with a second line of treatment within 12 months of their prostate cancer diagnosis.
They found that men suffer significant declines in their HRQOL after receiving primary any primary treatment and that the impact of second line therapy in the surgery group on their HRQoL was significant and greater than primary treatment alone.
J Clin Oncol 34, 2016 (suppl; abstr 5054)
Alsinnawi, Cullen, Hurwitz, Banerji, etal.